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Abstract
Background: Somatostatin (SST) inhibits intracellular cyclic adenosine monophosphate (cAMP) production and thus
may modify cyst formation in autosomal dominant polycystic kidney disease (ADPKD). We investigated whether
endogenous plasma SST concentration is associated with disease severity and progression in patients with ADPKD,
and whether plasma SST concentrations change during treatment with a vasopressin V2 receptor antagonist or SST
analogue.
Methods: In this observational study, fasting concentrations of SST were measured in 127 ADPKD patients
(diagnosed upon the revised Ravine criteria) by ELISA. cAMP was measured in 24 h urine by Radio Immuno Assay.
Kidney function was measured (mGFR) as 125I-iothalamate clearance, and total kidney volume was measured by MRI
volumetry and adjusted for height (htTKV). Disease progression was expressed as annual change in mGFR and
htTKV. Additionally, baseline versus follow-up SST concentrations were compared in ADPKD patients during
vasopressin V2 receptor antagonist (tolvaptan) (n = 27) or SST analogue (lanreotide) treatment (n = 25).
Results: In 127 ADPKD patients, 41 ± 11 years, 44% female, eGFR 73 ± 32 ml/min/1.73m2, mGFR 75 ± 32 ml/min/1.
73m2 and htTKV 826 (521–1297) ml/m, SST concentration was 48.5 (34.3–77.8) pg/ml. At baseline, SST was
associated with urinary cAMP, mGFR and htTKV (p = 0.02, p = 0.004 and p = 0.02, respectively), but these associations
lost significance after adjustment for age and sex or protein intake (p = 0.09, p = 0.06 and p = 0.15 respectively).
Baseline SST was not associated with annual change in mGFR, or htTKV during follow-up (st. β = − 0.02, p = 0.87 and
st. β = − 0.07, p = 0.54 respectively). During treatment with tolvaptan SST levels remained stable 38.2 (23.8–70.7) pg/
mL vs. 39.8 (31.2–58.5) pg/mL, p = 0.85), whereas SST levels decreased significantly during treatment with lanreotide
(42.5 (33.2–55.0) pg/ml vs. 29.3 (24.8–37.6), p = 0.008).
Conclusions: Fasting plasma SST concentration is not associated with disease severity or progression in patients
with ADPKD. Treatment with lanreotide caused a decrease in SST concentration. These data suggest that plasma
SST cannot be used as a biomarker to assess prognosis in ADPKD, but leave the possibility open that change in SST
concentration during lanreotide treatment may reflect therapy efficacy.
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Background
Autosomal dominant polycystic kidney disease (ADPKD)
is characterized by progressive cyst formation in both
kidneys, leading to kidney enlargement and loss of renal
function [1]. On a cellular level the disease is character-
ized by dysregulated calcium influx in tubular epithelial
cells and increased intracellular levels of cyclic adenosine
monophosfate (cAMP). In turn, cAMP stimulates cellu-
lar proliferation and dedifferentiation, and causes fluid
transport. These processes lead to dilation of tubules
and to cyst formation [2].
Somatostatin (SST) is a naturally occurring hormone
secreted mainly by cells of the nervous system, gastro-
intestinal tract and pancreatic islets. SST has an inhibi-
tory effect on the release of growth hormone, pancreatic
enzymes, and gastrointestinal peptides. In the kidney
SST has multiple effects including inhibition of cAMP
production [3] and inhibition of proliferation of renal
cells [4–6]. It is therefore hypothesized that SST may
have favorable effects in ADPKD. Indeed, randomized
clinical trials suggest that systemic administration of
SST analogues may be beneficial in slowing disease pro-
gression in ADPKD [7–9].
Given these findings, we hypothesized that endogenous,
systemic SST levels are involved in the pathophysiologic
cascade of ADPKD and therefore is associated with urin-
ary cAMP, disease severity and progression. Furthermore,
we hypothesized that administration of SST analogues
may down-regulate systemic SST, and that the degree of
systemic SST down-regulation may reflect therapy effi-
cacy. Furthermore, we hypothesized that SST levels may
change during treatment with a vasopressin V2 receptor
antagonist since this treatment effectively inhibits cyst for-
mation by suppressing cAMP levels [10, 11]. We therefore
investigated in subjects with ADPKD whether fasting
plasma concentration of endogenous SST is associated
with 1) urinary cAMP excretion 2) disease severity and 3)
disease progression, and 4) whether plasma SST concen-
tration changes on treatment with the vasopressin V2
receptor antagonist tolvaptan or the SST analogue
lanreotide.
Material and methods
Setting and subjects
For the first part of this study, all consecutive patients
with ADPKD visiting our out-patient clinic from January
2007 until September 2012 were asked to participate.
The diagnosis of APDKD was made based upon the re-
vised Ravine criteria [12]. Subjects were considered ineli-
gible in case they received renal replacement therapy,
had undergone renal surgery, were unable to undergo
MR imaging, had other medical conditions, systemic dis-
eases or treatments potentially affecting renal function
(such as pregnancy, lactation, diabetes mellitus, chronic
use of NSAIDs).
For the second part of this study, plasma SST was
measured in 2 additional groups of ADPKD patients,
who participated in a clinical trial investigating a vaso-
pressin receptor antagonist (n = 27) [13] and who partic-
ipated in a clinical trial using a somatostatin analogue
(n = 25) [14].
This study was performed in adherence to the declar-
ation of Helsinki and all participants gave written in-
formed consent allowing to use data for additional
analysis. The institutional review board of the University
Medical Center Groningen deemed this study exempt of
assessment because of its post-hoc exploratory nature.
Data collection and measurements
For the first part of our study, all ADPKD patients col-
lected a 24 h urine 1 day prior to the baseline visit. At
baseline blood pressure was assessed at rest in a supine
position with a semi-automatic, non-invasive sphygmo-
manometer (Dinamap) for 15 min and height and weight
were measured for the calculation of BMI and BSA (ac-
cording to the Dubois formula) [15]. Next, fasting blood
samples were drawn for the measurement of SST and
creatinine and for PKD mutation analyses. For the meas-
urement of GFR (mGFR), patients underwent a renal
function measurement by the constant infusion method
with 125I-Iothalamate at baseline and follow-up. MRI im-
aging was performed, both at baseline and follow-up for
the measurement of TKV, using a standardized abdom-
inal MRI imaging protocol with a 1.5-Tesla MR scanner
(Magneto Avanto, Siemens, Erlangen, Germany) and
with a 3.0 Tesla MR scanner (and Intera, Philips, Eind-
hoven, the Netherlands). We observed no differences in
quality, i.e. suitability for TKV measurement, of images
between both scanners in a previous study. We also ob-
served no differences in TKV measured on T1 versus T2
weighted images between both scanners [16]. Therefore
TKV measured on images of both MR scanners is com-
parable. Of note, a subset of patients (n = 26) underwent
an extra blood draw during a follow-up of 6 weeks for
the measurement of SST to study the stability of plasma
SST concentration over time.
We additionally measured SST in patients who partici-
pated in two clinical studies. Protocols of these studies
are described elsewhere [13, 14]. In short, patients were
invited for a baseline visit receiving standard care. Next,
patients were invited for a follow-up visit after 3 weeks
to 3 months receiving either tolvaptan 120 mg per day or
lanreotide 120mg s.c. every 4 weeks above standard care.
Protein intake was calculated as 24-h urinary urea ex-
cretion * 0.18 + 15 according to the Maroni formula [17]
and sodium intake as 24-h urinary sodium excretion.
cAMP was measured in 24 h urine in a competitive
Messchendorp et al. BMC Nephrology          (2018) 19:368 Page 2 of 10
protein-binding assay using a Radio Immuno Assay
(Amersham plc, UK). GFR was estimated (eGFR) using
the 2009 CKD-EPI (Chronic Kidney of Diet in Renal
Disease) Study equation [18]. TKV was measured on
T2-weighted coronal images using Analyze direct 9.0
(AnalyzeDirect, Inc., Overland Park, KS) with the man-
ual tracing method and adjusted for height (htTKV)
[19]. PKD mutation analysis was performed with DNA
isolation using PUREGENE™ nucleic acid purification
chemistry on the AUTOPURE LS 98 platform (Qiagen),
followed by sequencing of amplified coding exons dir-
ectly (exon 34–46), or on long-range PCR products
(exon 1–33) [20].
Somatostatin measurements
In this study we measured the concentration of bioactive
SST (Fig. 1) in fasting blood samples. Therefore, blood
was collected in EDTA tubes. All specimens were mixed
by gentle hand inversion at least six times following col-
lection. Samples were put on ice and separated immedi-
ately by centrifugation at 1580 g for 10 min at 4 degrees
Celsius.
First, plasma samples were extracted on SEP-columns
containing 200 mg of C18 (Strata, Phenomenex). The ex-
tracted samples were snap frozen by liquid nitrogen and
thereafter stored at − 80 °C. Within 1 week after extrac-
tion, 3 mL of each sample was freeze dried in a Christ
Epsilon 2–4 freeze dryer (Salm & Kipp, Breukelen, The
Netherlands), at − 45 °C for 24 h at a pressure of 0.220
mbar and a condenser temperature of − 85 °C to remove
water from the frozen samples. The dried extract was
kept at − 80 °C until the ELISA took place. Within 1
week after freeze drying, the ELISA was performed by
reconstitution of the dried extract, using 125 μL of assay
buffer and 50 μL was aliquoted into designated assay
wells using a commercially available ELISA kit (Phoenix
pharmaceuticals Inc. Burlingame, California, USA). Con-
centrations were expressed as pg/mL. The intra- and
inter-assay coefficient of variation (CV) of the SST
ELISA were 2.4 and 7.6% respectively. The additional
CV due to the extraction step with SEP-COLUMNS was
7.7%. Spiking with 50 and 100 pg SST-14 resulted in a
median ratio of 1.14 (0.96–1.59) between measured and
expected SST concentration. To minimize variability,
multiple samples of an individual were assessed on one
plate.
Statistical analysis
Normally distributed data are expressed as means ± stand-
ard deviation, whereas non-normally distributed data are
expressed as median with interquartile range (IQR). Dif-
ferences between groups were tested using a 2-sample t
test when normally distributed or a Mann-Whitney test
when not normally distributed. Pearson Correlation was
used to investigate the stability of SST measured twice
over time.
Potential determinants of SST concentration were inves-
tigated using linear regression analysis. Associations with
SST were tested univariably and multivariably in a step-
wise backward analysis. Next, we investigated the associ-
ation of SST concentration with urinary cAMP excretion,
mGFR and htTKV cross-sectionally and with annual
change in mGFR and htTKV longitudinally. We tested as-
sociations crude and after adjustment for covariates. Only
patients with a follow-up time of ≥1 year were selected for
the longitudinal analyses. Annual change in mGFR and
htTKV were calculated as follow-up minus baseline value
divided by follow-up time in years. SST was log trans-
formed to fulfill the requirement of normal distribution of
the residuals for the linear regression analyses. Outliers in
SST were defined as values above or below two times the
Fig. 1 Somatostatin, its precursors and cleavage products (modified from chapter 9 of handbook of physiology by Patel et al. [26]). SST is synthesized
as part of a large precursor protein, preproSST, located on the long arm of chromosome 3 and is rapidly cleaved into the prohormone form, proSST.
ProSST is further enzymatically processed in two bioactive forms, SST-14 and SST-28 .These forms are both measured in the assay we used.
Abbreviations are: SST, somatostatin
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standard deviation of the mean of the log transformed
SST values.
As sensitivity analysis we repeated the analysis with
eGFR cross-sectionally and with annual change in eGFR
calculated as slope longitudinally, with slope calculated
by at least 3 eGFR measurements over > 1 year.
We compared SST levels in patients receiving stand-
ard care at baseline and standard care plus tolvaptan or
lanreotide at follow-up using a Related-Samples Wil-
coxon Signed Rank Test. A Mann-Whitney U test was
performed to compare SST levels between the two
groups.
Analyses were performed with SPSS version 23.0
(SPSS Inc., Chicago, IL). A two sided p < 0.05 was con-
sidered statistical significant.
Results
Patients and somatostatin concentration at baseline and
over time
SST was measured in a total of 127 ADPKD patients for
cross-sectional analyses. All patients had mGFR values
and 121 patients had TKV values available. Baseline
characteristics of patients are presented in Table 1.
In a subset of 26 ADPKD patients, SST measurement
was repeated during a follow-up of 42 ± 1 days. In this
subset, SST levels were stable (40.8 (IQR 25.3–72.6;
range 98.2) vs. 37.29 (IQR 24.67–72.12; range 107) pg/
mL, p = 0.69), represented by Fig. 2 as the regression line
follows the line of identity and showed a strong correl-
ation (st. β = 0.73, p < 0.001).
Possible determinants of somatostatin concentration at
baseline
In ADPKD patients sex, age, protein intake and coffee
use were univariably associated with SST concentration.
When performing a multivariable stepwise backward
analysis both age and protein intake remained associated
with SST, indicating that these two variables are the
most important determinants of SST concentration
(Table 2).
Somatostatin concentration and urinary cAMP at baseline
The mean urinary cAMP excretion was 3.89 ± 1.27 μmol/
24 h. The level of cAMP excretion is, among others,
dependent on the level of functioning kidney tissue (in
our cohort, β = 7.18 and st. β = 0.34, p = 0.003 between
cAMP excretion and mGFR). Therefore, we adjusted
cAMP excretion for mGFR. Plasma SST was univariably
associated with mGFR (adjusted urinary cAMP excretion)
(β = 0.02 and st. β = 0.27, p = 0.02), however after adjust-
ment for age and protein intake this association lost sig-
nificance (β = 0.01 and st. β = 0.21, p = 0.09).
Somatostatin concentration and disease severity at
baseline
Table 3 shows the association of SST concentration with
mGFR and htTKV. SST concentration was significantly
associated with mGFR and htTKV. After adjustment for
age and sex no association remained significant. Of note,
also additional adjustment for renal function (in case of
htTKV) or htTKV (in case of mGFR), and protein intake
did not result in significant associations of SST with
mGFR and htTKV. After excluding 4 outliers (subjects
with a SST level of 1.05, 4.10, 9.50 and 343.67 pg/mL),
SST remained associated with mGFR (β = − 29.0 and st.
β = − 0.22, p = 0.01), but the association with htTKV lost
significance (β = 0.09 and st. β = 0.08, p = 0.40). Of note,
when excluding these 4 outliers, it was again noted that
Table 1 Baseline characteristics of ADPKD patients
Standard care Tolvaptan Lanreotide
N 127 27 25
Age (yrs) 40.9 ± 11.0 46.3 ± 9.8 47.4 ± 9.7
Female, n (%) 56 (44.1) 12 (48.1) 11 (44.0)
BMI (kg/m2) 26.0 ± 4.6 25.7 ± 4.1 27.7 ± 5.4
BSA (m2) 2.03 ± 0.25 2.02 ± 0.28 2.04 ± 0.25
SBP (mm Hg) 128 ± 12.2 131 ± 10.7 140 ± 10.6
DBP (mm Hg) 78.7 ± 9.23 81.3 ± 7.6 88.1 ± 8.3
AHT n, (%) 99 (78.0) 24 (88.9) 22 (88.0)
Sodium intake
(mmol/24 h)
170 ± 68.9 202 ± 92.7 168 ± 59.0
Protein intake
(g/24 h)
85.7 ± 21.0 110 ± 38.5 67.8 ± 16.7
Coffee use
(cups/day)
3 (1–5) NA NA
eGFR
(ml/min/1.73m2)
72.5 ± 31.6 57.0 ± 33.1 51.0 ± 11.6
mGFR
(ml/min/1.73m2)
75.2 ± 32.0 60.8 ± 34.7 NA
htTKV (mL/m) 826 (521–1297) 1242 (608–1505) 1150 (650–1833)
PKD mutation, n (%)
PKD1 truncating 48 (37.8) 3 (11.1) 9 (36.0)
PKD1
non-truncating
30 (23.6) 5 (18.5) 8 (32.0)
PKD2 13 (10.2) 4 (14.8) 4 (16.0)
No mutation
detected
2 (1.6) 0 (0.0) 0 (0.0)
Missing 34 (26.8) 15 (55.6) 4 (16.0)
Somatostatin
(pg/mL)
48.5 (34.3–77.8) 38.2 (23.8–70.6) 42.5 (33.2–55.0)
Variables are presented as mean ± SD when normally distributed, when non-
normally distributed as median (IQR)
Abbreviations are: N number, BMI body mass index, BSA body surface area, SBP
systolic blood pressure, DBP diastolic blood pressure, eGFR estimated
glomerular filtration rate, mGFR measured glomerular filtration rate, htTKV
height adjusted total kidney volume, PKD polycystic kidney disease, NA
not available
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the association of SST with mGFR lost significance after
adjustment for age and sex (β = − 16.3 and st. β = − 0.13, p
= 0.09). Results with eGFR were similar compared to
mGFR (Additional file 1). We found no differences in SST
levels between CKD stages (Additional file 2).
Somatostatin concentration and disease progression
during follow-up
Thirty patients were excluded for the longitudinal analyses
because they were either lost to follow-up or had a follow up
time < 1 year, leaving 97 patients. Seventy-eight patients had
follow-up mGFR and 77 patients follow-up TKV data avail-
able. Mean follow-up time of these patients was 3.8 ± 1.3
years for mGFR and 3.8 ± 1.1 years for htTKV. The annual
rate of mGFR decline was − 3.17 ± 2.99ml/min/1.73m2 per
year and the annual rate of htTKV growth was 6.37 ± 5.70%
per year. Baseline SST concentration was not signifi-
cantly associated with either annual change in mGFR
or htTKV (β = − 0.17, st. β = − 0.02, p = 0.87 and β = − 1.18,
st. β = − 0.07, p = 0.54 respectively) (Fig. 3). Of note, add-
itional adjustment for age, sex, baseline htTKV (in case of
annual change in mGFR), baseline mGFR (in case of
annual change in htTKV), PKD mutation and protein in-
take did not materially change these associations (β = 0.66,
st. β = 0.07, p = 0.51 and β = − 2.08, st. β = − 0.12, p = 0.32,
respectively). Excluding 4 outliers (subjects with a SST
Fig. 2 Correlation between plasma somatostatin at week 0 and week 6, with solid line representing the line of identity, and dotted line the
actual regression line. The regression line is calculated by orthogonal linear regression analysis and standardized beta and p-value is calculated by
Pearson Correlation
Table 2 Potential determinants of SST concentration in ADPKD
patients receiving standard care (n = 127)\
Univariable Multivariable
Stepwise backward
St. β p-value St. β p-value
Female sex −0.20 0.02
Age (yrs) 0.18 0.04 0.19 0.03
BMI (kg/m2) −0.01 0.92
AHT use −0.06 0.48
SBP (mmHg) −0.04 0.70
DBP (mmHg) −0.05 0.60
Sodium intake (mmol/24 h) 0.06 0.50
Protein intake (g/24 h) 0.19 0.04 0.20 0.03
Coffee use (cups/day) 0.20 0.04
PKD2 (ref)a
PKD1 truncating −0.10 0.53
PKD1 non-truncating −0.09 0.59
Standardized beta’s and p-values were calculated using linear regression
analysis. Dependent variable is the log transformed SST concentration,
independent variables are sex, age, BMI, AHT, SBP, DBP, sodium intake, protein
intake and coffee use
Abbreviations are: BMI body mass index, AHT antihypertensive therapy, SBP,
systolic blood pressure, DBP diastolic blood pressure, PKD polycystic kidney
disease, St. β standardized beta
aPKD mutation was used as dummy variable with PKD2 as reference group
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level of 1.05, 4.10, 9.50 and 343.67 pg/mL) did not change
the results. Similar results were found when annual change
in eGFR calculated as slope instead of annual change in
mGFR was studied (Additonal file 1).
Somatostatin concentration during tolvaptan or
lanreotide therapy
We compared SST levels of ADPKD patients receiving
standard care at baseline and either tolvaptan (n = 27) or
lanreotide (n = 25) above standard care at follow-up.
These two groups consisted of patients with a similar
age (46.3 ± 9.8 vs. 47.4 ± 9.7 years, p = 0.69), sex distribu-
tion (48% vs. 44% female, p = 0.79), eGFR (57.0 ± 33.1 vs.
50.9 ± 11.5 ml/min/1.73m2, p = 0.38) and htTKV (1242
(608–1504) vs. 1150 (650–1833) ml/m, p = 0.75)
(Table 1). In patients receiving tolvaptan, SST levels
remained stable (38.2 (IQR 23.8–70.7; range 98.2) pg/
mL vs. 39.8 (IQR 31.2–58.5; range 295) pg/mL, p = 0.85),
whereas in patients receiving lanreotide, SST levels de-
creased (42.5 (IQR 33.2–55.0; range 45.3) pg/mL vs. 29.3
(IQR 24.8–37.6; range 43.0) pg/mL, p = 0.008) (Fig. 4).
SST levels of both groups were similar at baseline
(p = 0.87) but lower in patients receiving lanreotide
at follow-up (p = 0.007).
Discussion
In the present study, we did not find an association be-
tween SST and urinary cAMP excretion, disease severity
or disease progression. This suggests that plasma SST is
not involved in the pathophysiology of ADPKD. How-
ever, we did find lower levels of plasma SST during
treatment with lanreotide, whereas plasma SST levels
remained stable during treatment with tolvaptan.
An important determinant of plasma SST is nutri-
tion [21]. To ensure optimal standardization, we drew
fasting blood samples for the measurement of SST.
We subsequently investigated if there were determi-
nants of plasma SST in our study population and
found that univariably sex, age, protein intake and
coffee use were significantly associated with SST.
Both age and protein intake remained associated with
SST in the multivariable stepwise backward analysis,
indicating that these variables may be determinants of
plasma SST concentration. That age is associated with
plasma SST concentration, with higher SST levels
Table 3 Association of plasma SST concentration with parameters of disease severity in patients receiving standard care
Crude Model 1 Model 2 Model 3 Model 4
St. β p St. β p St. β p St. β p St. β p
Baseline mGFR (ml/min/1.73m2)
Log SST −0.25 0.004 −0.13 0.06 −0.10 0.14 −0.10 0.21 −0.12 0.14
Female sex 0.05 0.47 −0.02 0.75 −0.02 0.79 0.03 0.76
Age (yrs) −0.59 < 0.001 −0.57 < 0.001 −0.63 < 0.001 −0.62 < 0.001
htTKV (ml/m) −0.33 < 0.001 −0.34 < 0.001 −0.34 < 0.001
PKD2 (ref)a
PKD1 truncating −0.30 0.02 −0.29 0.02
PKD1 non-truncating −0.27 0.03 −0.26 0.03
Protein intake (g/24 h) 0.14 0.10
Baseline log htTKV
Log SST 0.21 0.02 0.13 0.15 0.06 0.50 0.05 0.62 0.04 0.71
Female sex −0.26 0.004 −0.23 0.004 −0.24 0.02 −0.21 < 0.05
Age (yrs) 0.17 0.05 −0.15 0.13 −0.16 0.22 −0.16 0.22
mGFR (ml/min/1.73m2) −0.55 < 0.001 −0.56 < 0.001 −0.57 < 0.001
PKD2 (ref)a
PKD1 truncating −0.05 0.73 −0.05 0.74
PKD1 non-truncating −0.15 0.31 −0.15 0.31
Protein intake (g/24 h) 0.07 0.50
Standardized beta’s and p-values were calculated using linear regression analysis. Dependent variable is mGFR or log transformed htTKV, independent variable is
the log transformed SST concentration
Abbreviations are: SST somatostatin, mGFR measured GFR, htTKV height adjusted total kidney volume, PKD polycystic kidney disease St. β, standardized beta, p p-value
Model 1: adjusted for age and sex
Model 2: adjusted for age, sex and htTKV or mGFR
Model 3: adjusted for age, sex and htTKV or mGFR and PKD mutation
Model 4: adjusted for age, sex and htTKV or mGFR, PKD mutation and protein intake
aPKD mutation was used as dummy variable with PKD2 as reference group
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with increasing age, is confirmed by other studies that
investigated SST in relation to growth hormone con-
centration [22–25]. The exact mechanism why SST
increases with age is not completely understood, but
there is evidence that this is related to changes in
sex- and growth hormone levels [23]. The association
of protein intake with plasma SST concentration can
be explained since ingestion of proteins gives rise to
gastrin release, that in turn stimulates SST secretion
[21]. Accordingly, we adjusted all our further analyses
for age and protein intake.
Only limited data is available on plasma concentration
of endogenous SST and its physiological effects on the
kidney. To our knowledge this is the first study investi-
gating associations of systemic plasma concentration of
SST in relation to a kidney disease, specifically ADPKD.
The results lead us to reject our hypothesis that plasma
SST is associated with urinary cAMP excretion, disease
severity and disease progression in ADPKD. An explan-
ation might be the balance between plasma SST concen-
tration and SST receptor affinity. There are five SST
receptor subtypes (SST receptor 1–5) and SST-14 and
SST-28 have for instance an affinity for the SST receptor
1 between 0.1 and 2.26 nM and for the SST receptor 2
between 0.2 and 4.1 nM, with affinity expressed as the
concentration required for obtaining 50% of the max-
imum effect mediated by the receptor (EC50) [21]. Im-
portantly, the median fasting SST concentration in our
ADPKD cohort was 48.5 (34.3–77.8) pg/mL, which is
equivalent to approximately 0.03 nM, much lower than
these EC50’s. Of note, these concentrations are compar-
able to that found in healthy subjects in other studies
(14–32.5 pg/ml) [26]. Our findings suggest that systemic
plasma SST concentration is not involved in the patho-
physiology of ADPKD. However, this does not neces-
sarily deny a role for SST in the pathophysiology of
ADPKD. SST is mainly produced at local sites of ac-
tion, thereby eliciting a paracrine/autocrine action.
For example for the stimulation of growth hormone,
SST is released from cells in the hypothalamus adja-
cent to the cells that secrete growth hormone, and
for the inhibition of pancreatic insulin secretion, the
δ cell in the pancreas releases SST. A similar mech-
anism has been suggested for the kidney; in-vitro
studies showed that mesangial cells and proximal tubular
cells itself produce SST [6, 27]. This suggests that circulat-
ing concentrations of SST, that probably consist mainly of
SST secreted from the gastro-intestinal tract [28–31], do
not reflect the SST concentrations locally at tissue level
for instance in the kidney.
By its paracrine/autocrine property, SST can elicit an
organ specific action, despite its broad systemic effects
on various SST receptors. To allow such organ specific
actions, SST is rapidly inactivated following local release
by peptidases in blood, but also by peptidases at tissue
level, thereby minimizing unwanted systemic effects. Ex-
ogenous SST analogues, that are used as therapeutic
agents, elicit their specific effects by having more affinity
for one receptor than for the other. Furthermore, these
SST analogues have a considerably longer half-life than
endogenous SST, which makes these SST analogues clin-
ically applicable as a drug, in contrast to endogenous
SST.
Fig. 3 Association between baseline SST and annual change in mGFR
(panel a) or annual change in htTKV (panel b) in patients with ADPKD
receiving standard care. Standardized beta’s and p-values were
calculated by linear regression analysis
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Lanreotide, which is a SST analogue, has nanomolar
affinity for only SST receptor 2 (EC50: 0.5–1.8 nM) and
SST receptor 5 (EC50: 0.6–14 nM). These receptors are
predominantly expressed in the brain, gastro-intestinal
tract and kidneys, while endogenous SST-14 and SST-28
have nanomolar affinity for all of the five receptor sub-
types. Furthermore, lanreotide has a plasma half-life of
25.5 days which is much longer than that of endogenous
SST [21, 32]. Therapy with lanreotide 90mg reaches mean
plasma concentrations of 4455 pg/mL [21, 32], which is
equivalent to approximately 2.7 nM. The renal SST recep-
tors can easily be triggered by these concentrations of lan-
reotide and elicit effects involved in inhibiting disease
progression in ADPKD. This is currently being investi-
gated in several randomized clinical trials [14]. In the
present study we showed in a small subset of included
ADPKD patients, that plasma levels of endogenous SST
decrease during treatment with lanreotide. It may be
that this decline in plasma SST levels during adminis-
tration of lanreotide reflects the extent to which SST
receptors are triggered, and thus indirectly reflects ef-
ficacy of lanreotide treatment in ADPKD patients.
This exciting option has to be investigated in pro-
spective studies. We hypothesized that during treat-
ment with the vasopressin V2 receptor antagonist
tolvaptan, SST levels may also change. It is known
that SST can inhibit cAMP production but cAMP in
turn can stimulate SST secretion [21]. Furthermore, it
is suggested that SST has a modulating effect on di-
uresis [33–36]. Since tolvaptan can effectively slow
the rate of disease progression in ADPKD by inhibit-
ing renal cAMP production [10, 11] and stimulate di-
uresis by blocking vasopressin at the collecting duct,
SST levels could theoretically be influenced during
treatment with tolvaptan. However, we found no dif-
ferences in systemic SST levels during treatment with
tolvaptan. Since tolvaptan acts locally in the collecting
duct of the kidney it could again be that only locally
produced SST levels change during treatment with
tolvaptan.
It should be noted that the present study has a num-
ber of limitations. First, we used biobanked blood sam-
ples that were collected without exogenous protease
inhibitors, whereas some have suggested that the use of
such inhibitors leads to more reliable assessment of SST
levels. Moreover, we found relatively high inter-assay
CV’s of the SST measurement. However, we found an
excellent yield of measured and expected SST concentra-
tion in plasma samples spiked with exogenous SST (ratio
1.14 (0.96–1.59)). In addition, we found a strong correl-
ation between SST levels measured twice in a subset of
ADPKD patients (Fig. 3). We conclude therefore that
Fig. 4 Plasma somatostatin concentration of patients receiving standard care at baseline and either tolvaptan or lanreotide above standard care
at follow-up. Data are expressed as Tukey boxplots with median, IQR, and minimum and maximum within 1.5 IQR and outliers. * Indicate outliers
outside the graph. P-values were calculated with a Related-Samples Wilcoxon Signed Rank Test in case of dependent measurements, and a
Mann-Whitney U test in case of independent measurements
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the samples and assay are sufficiently reliable to detect
associations and changes in SST within a patient.
Strengths of our study are that this is the first study in-
vestigating plasma SST in relation to a renal disease.
Second, we had detailed follow-up data available for our
patients, with gold standard measurements of disease
progression (change in mGFR and TKV) enabling us to
investigate longitudinal associations of baseline plasma
SST with the rate of disease progression. We also inves-
tigated change in plasma SST levels during treatment
with the vasopressin V2 receptor antagonist tolvaptan
and the SST analogue lanreotide.
Conclusions
This study demonstrates that fasting plasma concentra-
tion of SST was not associated with urinary cAMP ex-
cretion, disease severity or disease progression in
patients with ADPKD.
Additional files
Additional file 1: Multivariable linear regression analysis of the
association of SST concentration with eGFR at baseline (n = 127) (upper
panel) or annual change in eGFR calculated as slope through multiple
(≥3) eGFR values at follow-up (n = 97) (lower panel). (DOCX 24 kb)
Additional file 2: Somatostatin levels according to CKD stage in
patients receiving standard care. Data are expressed as Tukey boxplots
with median, IQR, and minimum and maximum within 1.5 IQR and
outliers (TIF 381 kb)
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